Tolerogenic Dendritic Cell Identity for the Treatment of Immune‐Mediated Diseases: A Signalling–Metabolism–Epigenetic Axis
Immunology · 09.11.2026
DOI: 10.1111/imm.70226 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 09.11.2026. Verfasst von Min-Ji Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Life Sciences and Department of Life Science, Graduate School of CHA University, Seongnam, Republic of Korea. Die Arbeit nennt 87 Literaturangaben. Gefördert von: Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Tolerogenic dendritic cells (tolDCs) maintain immune tolerance by suppressing effector T cells while inducing regulatory T cells (Treg). Importantly, tolDCs play critical roles in suppressing pathogenic activation and maintaining homeostasis in immune‐mediated diseases. This highlights the need to define the molecular mechanisms sustaining their stable tolerogenic identity. Although tolDCs are typically characterized by downregulated co‐stimulatory molecules and upregulated anti‐inflammatory cytokines, this phenotype alone fails to fully define their tolerogenic nature. Emerging evidence links signalling pathways, metabolic adaptation and epigenetic regulation in shaping the tolDC landscape. While acting through different initial receptors, distinct tolerogenic stimuli─such as 1,25‐dihydroxyvitamin D3 (VitD3), dexamethasone (Dex) and rapamycin─converge on core signalling regulators, including mammalian target of rapamycin (mTOR), AMP‐activated protein kinase (AMPK) and signal transducer and activator of transcription 3 (STAT3). These central checkpoints directly drive metabolic reprogramming, encompassing oxidative phosphorylation (OXPHOS), fatty acid oxidation (FAO), tricarboxylic acid (TCA) cycle and glycolysis. These metabolic adaptations subsequently reshape chromatin organization through metabolite‐dependent regulation of DNA methylation and histone modification. Accordingly, metabolite‐mediated epigenetic remodelling effectively locks these pathways to stabilize the tolerogenic state, fixing the enzymatic and secretome programmes required for robust Treg polarization despite phenotypic plasticity. This review discusses the signalling pathways driving tolerogenic metabolic adaptation, the mechanisms linking metabolism to epigenetic regulation and the implications of this signalling–metabolism–epigenetic axis for tolDC identity, immune regulation and therapeutic applications in immune‐mediated and inflammatory diseases, as well as in transplantation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Life Sciences and Department of Life Science, Graduate School of CHA University, Seongnam, Republic of Korea.
- Samda BioLab. Co., Ltd., Goyang, Republic of Korea.
- Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.
ORCID-Profile: Jie-Young Song, Dae-Seog Lim
Förderung
- Ministry of Science and ICT, South Korea
Zitieren
APA
Kim, M. J., Song, M. S., Jung, N. C., Song, J. Y., & Lim, D. S. (2026). Tolerogenic Dendritic Cell Identity for the Treatment of Immune‐Mediated Diseases: A Signalling–Metabolism–Epigenetic Axis. Immunology. https://doi.org/10.1111/imm.70226
Vancouver
Kim MJ, Song MS, Jung NC, Song JY, Lim DS. Tolerogenic Dendritic Cell Identity for the Treatment of Immune‐Mediated Diseases: A Signalling–Metabolism–Epigenetic Axis. Immunology. 2026. doi:10.1111/imm.70226
BibTeX
@article{Kim2026,
author = {Kim, Min-Ji and Song, Min-Seon and Jung, Nam-Chul and Song, Jie-Young and Lim, Dae-Seog},
title = {Tolerogenic Dendritic Cell Identity for the Treatment of Immune‐Mediated Diseases: A Signalling–Metabolism–Epigenetic Axis},
journal = {Immunology},
year = {2026},
doi = {10.1111/imm.70226}
}
EUVIMED